Journal
REVISTA ESPANOLA DE CARDIOLOGIA
Volume 74, Issue 7, Pages 608-615Publisher
EDICIONES DOYMA S A
DOI: 10.1016/j.recesp.2020.12.014
Keywords
COVID-19; SARS-CoV-2; Mortality; Registry; Prognosis; Atrial fibrillation; CHA2DS2-VASc; Bleeding
Categories
Ask authors/readers for more resources
Atrial fibrillation (AF) in COVID-19 patients is associated with a higher number of complications and a higher 60-day mortality rate. The CHA(2)DS(2)-VASc score may be a good risk marker in COVID patients but does not predict their embolic risk.
Introduction and objectives: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2. Atrial fibrillation (AF) is common in acute situations, where it is associated with more complications and higher mortality. Methods: Analysis of the international HOPE registry (NCT04334291). The objective was to assess the prognostic information of AF in COVID-19 patients. A multivariate analysis and propensity score matching were performed to assess the relationship between AF and mortality. We also evaluated the impact on mortality and embolic events of the CHA(2)DS(2)-VASc score in these patients. Results: Among 6217 patients enrolled in the HOPE registry, 250 had AF (4.5%). AF patients had a higher prevalence of cardiovascular risk factors and comorbidities. After propensity score matching, these differences were attenuated. Despite this, patients with AF had a higher incidence of in-hospital complications such as heart failure (19.3% vs 11.6%, P= .021) and respiratory insufficiency (75.9% vs 62.3%, P = .002), as well as a higher 60-day mortality rate (43.4% vs 30.9%, P = .005). On multivariate analysis, AF was independently associated with higher 60-day mortality (hazard ratio, 1.234; 95%Cl, 1.003-1.519). CHA(2)DS(2)-VASc score acceptably predicts 60-day mortality in COVID-19 patients (area ROC, 0.748; 95%CI, 0.733-0.764), but not its embolic risk (area ROC, 0.411; 95%Cl, 0.147-0.675). Conclusions: AF in COVID-19 patients is associated with a higher number of complications and 60-day mortality. The CHA(2)DS(2)-VASc score may be a good risk marker in COVID patients but does not predict their embolic risk. (C) 2021 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available